Tag: Low-risk MDS treatment

Home / Low-risk MDS treatment

Categories

Imetelstat is approved by FDA for low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia

  May 2024: Imetelstat (Rytelo, Geron Corporation), an oligonucleotide telomerase inhibitor, has been approved by the Food and Drug Administration for use in adults with low- to intermediate-1...
low-risk-mds-treatment

Scan the code